Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 17/20 | 0.43 |
| ▸ | THRA | P10827 | 16/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700899 | 0.80 | THRB (0.50) | THRBTHRA | |
| SCHEMBL6700091 | 0.79 | THRB (0.46) | THRBTHRA | |
| SCHEMBL6692400 | 0.72 | THRB (0.64) | THRBTHRA | |
| SCHEMBL6690833 | 0.71 | THRB (0.57) | THRBTHRA | |
| SCHEMBL6695033 | 0.70 | THRB (0.59) | THRBTHRA | |
| SCHEMBL6695738 | 0.70 | THRB (0.53) | THRBTHRA | |
| SCHEMBL4426106 | 0.68 | THRB (0.83) | THRBTHRA | |
| SCHEMBL6695591 | 0.68 | PDE4D (0.42) | THRBTHRAEGFRCYP2C9CYP2C19 | |
| SCHEMBL2787292 | 0.63 | THRB (0.71) | THRBTHRA | |
| SCHEMBL14489280 | 0.63 | THRB (0.64) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885EGFR 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.